Laboratory Corp. of America Holdings

Laboratory Corporation of America Holdings is a life sciences company engaged in providing clinical laboratory and end-to-end drug development services. The company reports its business in two segments: LabCorp Diagnostics, which provides a menu of testing through an integrated network of primary and specialty laboratories across the U.S., supported by an information technology system, logistics, local labs providing testing, and also provides patient access points located throughout the U.S.; and Covance Drug Development, which provides end-to-end drug development, medical device and diagnostic development solutions from early-stage research to clinical development and commercial market access.
  • TickerLH
  • ISINUS50540R4092
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

Laboratory Corp Of America Holdings: 1 director sold

A director at Laboratory Corp Of America Holdings sold 31,250 shares at 160.000USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules...

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 Getting Long-Term Oversold Note: We have suspended the Russell grids and Sector comments this week due to heightened volatility. Major indexes broke below the key support levels we were watching on the Nasdaq Composite (8,264), S&P 500 (2,855), DJI (24,681) and Russell 2000 (1,448), ushering-in additional downside. We view these levels as logical areas of potential short-term resistance moving forward. Clues that a breakdown was increasingly likely started coming as early as Thursday, when the KBW Bank index broke below key $89 support we outlined last week. Friday's widening move in h...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • No one knows just how the COVID-19 plays out, but yes, at some point this too will pass. We would expect volatility to continue and headlines to trump (pun not intended) trends. The divergence between Technology and the Energy, Materials, and Industrials Sectors has been disturbing to us for some time. Small-Caps and emerging markets have been lagging the Tech heavy S&P 500 significantly as well. • We believe that widening spreads between high-yield corporates and 10-yr Treasuries could be the canary in the coal mine. A decisive break above the trend line may usher in a much m...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Consumer Cyclical names continue to reflect leadership. (ex. SBUX, RRGB, MCD, PZZA, and ROST.) • The Financial Sector has a number of attractive names developing major bases and staging RS reversals. (ex. SIVB, STT, AXP, SPGI, CME, GS, and JEF) • The Technology Sector has a number of technically attractive constituents. (ex. AMD, OLED, MPWR, CRUS, BR, FIS, VRSN, SAIC, LDOS, AAOI, BELFB, FARO, STX, and AAPL) .

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Laboratory Corp Of America Holdings: 1 director sold

A director at Laboratory Corp Of America Holdings sold 31,250 shares at 160.000USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules...

Valens Research

Valens Equity Insights and Inflections - 2020 04 28

BZH currently trades below recent averages relative to Uniform earnings, with a 5.8x Uniform P/E (Fwd V/E'). At these levels, the market is pricing in expectations for Uniform ROA to decline from 13% in 2019 to 5% in 2024, accompanied by 3% Uniform asset contraction going forward. However, analysts have bullish expectations, projecting Uniform ROA to expand to 15% through 2021, accompanied by 2% Uniform asset growth. That said, management is excited about their efforts to simplify product offerings, and is confident about their EBITDA growth and Nashville openings. Current valuations appear to...

Valens Research

LH - Embedded Expectations Analysis - 2020 04 27

 Laboratory Corporation of America (LH:USA) currently trades near corporate averages relative to UAFRS-based (Uniform) earnings, with a 21.5x Uniform P/E. At these levels, markets have bearish expectations for the firm, but management is confident about their revenue growth, margin expansion, and free cash flow  Specifically, management is confident they expect a 3% revenue growth rate in 2020 when excluding unusual items, that their free cash flow improved from $926mn in 2018 to $1.04bn, and that they expect margins to improve again. In addition, they are confident they expect Covance orga...

Valens Research

Valens Equity Insights and Inflections - 2020 03 10

AMAT currently trades well below corporate averages relative to UAFRS-based (Uniform) Earnings with a 12.7x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to compress from 22% in 2019 to 15% in 2024, accompanied by 6% Uniform Asset growth going forward. However, analysts have diverging expectations, projecting Uniform ROA to expand to 28% in 2021, accompanied by 10% Uniform Asset growth. Meanwhile, management is confident about growth opportunities in display and memory, their growth positioning, and demand signals. Current valuations appear to be pricing i...

Valens Research

LH - Embedded Expectations Analysis - 2020 03 06

 Laboratory Corporation of America (LH:USA) currently trades near corporate averages relative to UAFRS (Uniform) Earnings, with a 21.6x Uniform P/E. At these levels, markets have bearish expectations for the firm, but management is confident about Covance revenue growth, improvements in margin trends, and the potential of companion oncology diagnostics  Specifically, management is confident that Covance revenue growth increased by more than 9%, LabCorp Diagnostics revenue increased to $1.8bn, and that their fourth quarter margins will be down less than they have been all year. In addition, ...

Moody's assigns Baa2 rating to LabCorp notes offering

Rating Action: Moody's assigns Baa2 rating to LabCorp notes offering. Global Credit Research- 19 Nov 2019. New York, November 19, 2019-- Moody's Investors Service assigned a Baa2 rating to the proposed offering of senior unsecured notes of Laboratory Corporation of America Holdings.

Laboratory Corporation of America Holdings: Update to credit analysis

LabCorp's credit profile is supported by the company's significant market presence and moderate leverage.

Laboratory Corporation of America Holdings: Update to credit analysis

LabCorp's credit profile is supported by the company's significant market presence and moderate leverage.

Moody's: LabCorp's Divestiture of Food Solutions Business is Credit Positive

Moody's Investors Service commented that the announcement by Laboratory Corporation of America Holdings ("LabCorp") to divest its Food Solutions business for $670 million is a credit positive. There is no impact on LabCorp's Baa2 ratings or stable outlook. For additional inform...

Laboratory Corporation of America Holdings: LabCorp's divestiture of Food Solutions business is credit positive

LabCorp's divestiture of Covance Food Solutions business will help in further reducing leverage.

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ValuEngine Rating and Forecast Report for LH

ResearchPool Subscriptions

Get the most out of your insights

Get in touch